Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926130 · ClinicalTrials.gov registry record · Phase 3
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,158
- Enrollment target
- 20
- Study locations
NCT03926130 is a Phase 3 study of Crohn's Disease that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,158 participants, below the 2,384-participant average among 105 other Crohn's Disease trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT03926130, a Phase 3 study of Crohn's Disease, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,158 participants
- Enrollment target
- 20
- Study locations
Study Summary
The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ustekinumab
- DRUG Mirikizumab
Study Locations (20)
California
- inSite Digestive Health Care - Arcadia
- B G Clinical Research, Inc. - Encinitas
- Care Access - Gilroy - Gilroy
- Newport Huntington Med Grp - Huntington Beach
- Om Research, LLC - Lancaster
- GastroIntestinal Biosciences Clinical Trials - Los Angeles
- California Medical Research Associates - Northridge
- University of California Irvine - Orange
- inSite Digestive Health Care - Pasadena
- Care Access Research - San Jose - San Jose
- Wolverine Clinical Trials, LLC - Santa Ana
Arizona
- Research Solutions of Arizona - Litchfield Park
- Central Arizona Medical Associates, PC - Mesa
- Arizona Arthritis & Rheumatology Research, PLLC - Phoenix
- Reliance Research - Scottsdale
- Synexus Site Network - Tempe
Alabama
- University of Alabama-The Kirklin Clinic - Birmingham
- Digestive Health Specialists - Dothan
- Lakeview Clinical Research - Guntersville
- Care Access Research - Tuscaloosa - Tuscaloosa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,158 participants |
| Start Date | 2019-07-23 |
| Est. Completion | 2023-10-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03926130
The ClinicalTrials.gov registry entry for NCT03926130 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,158 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,384-participant average among 105 other Crohn's Disease trials with a reported enrollment target (51% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03926130 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT03926130 about?
NCT03926130 is a clinical study titled "A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease". The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.
What is the current status of trial NCT03926130?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,158 participants. The study started on 2019-07-23. Estimated completion is 2023-10-02.
What conditions does trial NCT03926130 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT03926130?
The interventions under investigation include: Placebo (DRUG), Ustekinumab (DRUG), Mirikizumab (DRUG).
Who is sponsoring clinical trial NCT03926130?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03926130 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.